Geron issued patent for production of insulin-secreting cells from human embryonic stem cells

By Lisa Kerner

Erie, Pa., April 26 - Geron Corp. has been granted U.S. Patent No. 7,033,831, covering the production of insulin secreting cells from human embryonic stem cells (hESCs).

The patent covers methods of scalable production of pancreatic islet cells from hESCs for use in new cell-based treatments for diabetes, according to a company news release.

The company presented data earlier this year describing the differentiation of hESCs to produce cells that secrete insulin and glucagons, as well as express genetic markers consistent with human islet cells.

Geron scientists demonstrated that these cells also generate detectable human insulin upon glucose challenge in animal models.

Geron is a biopharmaceutical company located in Menlo Park, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.